Sanofi (NYSE:SNY)‘s stock had its “neutral” rating reaffirmed by stock analysts at Nord/LB in a note issued to investors on Wednesday.

SNY has been the subject of several other reports. Argus reaffirmed a “buy” rating and issued a $55.00 target price on shares of Sanofi in a research report on Friday, September 1st. Bank of America cut Sanofi from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 6th. Barclays raised Sanofi from an “underweight” rating to an “equal weight” rating in a research report on Wednesday, November 15th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Sanofi in a research report on Thursday, December 14th. Finally, Zacks Investment Research cut Sanofi from a “hold” rating to a “strong sell” rating in a research report on Friday, October 6th. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Sanofi presently has a consensus rating of “Hold” and a consensus price target of $51.50.

Shares of Sanofi (NYSE SNY) opened at $42.86 on Wednesday. Sanofi has a 12-month low of $39.26 and a 12-month high of $50.65. The company has a debt-to-equity ratio of 0.26, a current ratio of 1.59 and a quick ratio of 1.16. The firm has a market capitalization of $108,298.77, a P/E ratio of 10.93, a PEG ratio of 2.56 and a beta of 0.86.

A number of institutional investors have recently added to or reduced their stakes in SNY. Blair William & Co. IL raised its stake in Sanofi by 42.7% during the second quarter. Blair William & Co. IL now owns 18,824 shares of the company’s stock worth $902,000 after acquiring an additional 5,635 shares in the last quarter. Parallel Advisors LLC raised its stake in Sanofi by 42.5% during the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after acquiring an additional 875 shares in the last quarter. Pacad Investment Ltd. raised its stake in Sanofi by 55.6% during the second quarter. Pacad Investment Ltd. now owns 8,400 shares of the company’s stock worth $402,000 after acquiring an additional 3,000 shares in the last quarter. Bronfman E.L. Rothschild L.P. raised its stake in Sanofi by 142.8% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 3,567 shares of the company’s stock worth $171,000 after acquiring an additional 2,098 shares in the last quarter. Finally, Eagle Asset Management Inc. raised its stake in Sanofi by 12.8% during the second quarter. Eagle Asset Management Inc. now owns 6,505 shares of the company’s stock worth $311,000 after acquiring an additional 739 shares in the last quarter. Hedge funds and other institutional investors own 9.08% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Sanofi (SNY) Receives “Neutral” Rating from Nord/LB” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://theolympiareport.com/2017/12/27/sanofi-sny-receives-neutral-rating-from-nordlb.html.

About Sanofi

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Analyst Recommendations for Sanofi (NYSE:SNY)

Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.